BMI – Medxy AI

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

By MedXY 12/24/2025

Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemic sclerosis.

Cardiology Diabetes & Endocrinology news

Underweight in Type 2 Diabetes Raises Cardiovascular Risk — Severe Leanness Carries Greater Risk Than Obesity

By MedXY 12/02/2025

A nationwide Korean cohort found that underweight patients with Type 2 diabetes—especially those with severe underweight—have higher cardiovascular risk than normal-weight and even some obese patients, underscoring the need to screen and manage malnutrition, sarcopenia, and frailty in diabetes care.

news Orthopedics Radiology

T2 Mapping Detects BMI-Linked Cartilage Changes and Lateral Compartment Signal Differences in Population-Based Knee OA

By MedXY 11/02/2025

In a large population-based sample, cartilage T2 relaxation times correlated with BMI and were higher in knees with MRI-defined osteoarthritis, particularly in lateral cartilage subregions; T2 did not reflect patient-reported symptoms.

news Orthopedics Rheumatology

Partitioning Knee Osteoarthritis Genetic Risk by BMI Association Clarifies Prediction and Mechanisms

By MedXY 11/02/2025

Partitioning a knee osteoarthritis polygenic score into BMI-associated and BMI-independent components clarifies genetic contributions, improves interpretability, and offers a path to tailored prediction and prevention.

Diabetes & Endocrinology Internal Medicine Specialties

Revisiting Obesity Classification: Insights from a Population-Based Survey in Peru Using New Clinical Frameworks

By MedXY 10/19/2025

This review examines a landmark Peruvian study applying new obesity definitions that incorporate clinical dysfunction and adiposity measures beyond BMI, revealing substantial underdiagnosis with traditional approaches and ethnic variation in fat distribution.

Diabetes & Endocrinology Specialties

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

By MedXY 09/07/2025

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY 08/17/2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.